ERBB4, one member of the epidermal growth factor receptor (EGFR) family, plays a key role in physiological and pathological processes. Recently, we identified that ERBB4 played a protective role from chronic hepatitis B virus infection. However, the role of ERBB4 in hepatocellular carcinoma (HCC) is still unclear. Here, we explore the role of ERBB4 in the development of HCC using in vitro models, in vivo animal models and clinical samples of HCC. Liver-specific ERBB4 knockout alleles and full ERBB4 except heart knockout mice were used in this study. Liver inflammation and tumor models of mice were produced by carbon tetrachloride (CCl4) and diethylnitrosamine (DEN) administration, respectively. Commercial tissue arrays of 90 HCC patients with paired counterparts were used to evaluate the expression and the prognostic value of ERBB4. Genes altered in the setting of ERBB4 loss was studied by microarray analysis and further validated by real-time PCR. We have found that depletion of ERBB4 in mice leads to more severe injury and liver tumor formation and loss of ERBB4 contributes to the development of hepatocellular tumor. In clinic samples of HCC, ERBB4 is down-regulated and exhibit prognostic value of HCC patients. Mechanistically, loss of ERBB4 suppressed p53 expression by inhibiting the expression of the tumor suppressor tp53inp1. Our study uncovers ERBB4 as a suppressor in the development of HCC and implies an ERBB4-TP53INP1-P53 axis in HCC.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world (1, 2) . Chronic inflammation and persistent liver cell regeneration are precancerous lesions in HCC (3) . For example, about 80% HCC patients in China have a history of hepatitis B virus (HBV) infection (4) . Thus, factors involved in chronic inflammation and persistent liver cell regeneration may contribute to the development of HCC. Identifying key molecules in liver inflammation and its related HCC will not only help us understand its pathogenesis, but also provide potential methods for early diagnosis and treatment.
ERBB4, one member of the epidermal growth factor receptor (EGFR) family, is a kind of factor related to chronic inflammation in gut and liver (5, 6) . However, the role of ERBB4 in cancer is still controversial. ERBB4 acts as an oncogene and is a potential therapy target in melanoma (7) . In addition, ERBB4 promotes metastasis in Ewing sarcoma (8) . Inconsistently, ERBB4 can also promote cell cycle arrest and apoptosis in breast cancer cells (9, 10) . Recently, we identified ERBB4 as a protector from chronic HBV infection and other liver inflammation (6) . More interestingly, further evidence indicated that ERBB4 was one of the recurrent targeted genes of HBV integration in HCC (11) . Moreover, the data from The Cancer Genome Atlas (TCGA) revealed that many cancer tissues such as gastric cancer, colorectal cancer and HCC lost the expression of ERBB4 in cancerous tissue compared with its paired normal tissues. Here, using in vitro models, in vivo animal models and clinical samples of HCC, we found the suppressive role of ERBB4 in the development of HCC. The versatility of ERRB4 in cancer suggests that the mechanisms are still need to be determined in specific cancer type.
Materials and methods

Mice, liver inflammation and HCC models
Liver-specific ERBB4 knockout alleles (ERBB4 loxp/loxp ;Alb-cre) have been described previously (6) . Full ERBB4 mutant mice were rescued from embryonic lethality by transgenic ERBB4 overexpression in the heart (ERBB4 −/−heart ) (12). All mice were maintained under a 12/12 h light/dark cycle and received food ad libitum. Animal procedures were reviewed and approved by the Animal Care and Use Committee of Soochow University.
Carbon tetrachloride (CCl4) is a classic stimulator of chemical liver inflammation and is often used to study the liver inflammatory disease (13) . 20% CCl4 (diluted by oil) was injected into mice intraperitoneally (2.5 µl per gram of the mice weight) (6) . The mice were sacrificed after 18 weeks injection and assessed for the histological changes. Diethylnitrosamine (DEN) or DEN plus CCl4 induced liver tumor models were used in this study. In DEN-induced liver tumor model, mice were injected with a single dose of DEN (25 mg/kg, N0258-1G; Sigma-Aldrich) on postnatal week 2, and animals were sacrificed after week 32 to examine the tumor number per mouse, as described previously (14) . In DEN plus CCl4 induced liver tumor model, mice were injected with CCl4 twice a week from the weeks 6 to 20 after DEN injection on postnatal week 2. Then, the mice were sacrificed for further analysis.
Histologic assessment
Liver fixation in paraffin and hematoxylin and eosin (H&E) staining of 4 µm sections were performed using standard protocols. Liver histology was examined by light microscopy in a blinded fashion.
Serological and biochemical analyses
Venous blood was collected by bleeding of the retro-orbital sinus. Serum was separated after clotting. Alanine aminotransferase levels in serum were measured.
Immunohistochemical (IHC) staining and scoring
Commercial tissue microarrays (HLiv-HCC180Sur-01; Shanghai Outdo Biotech, China) from 90 HCC patients with paired counterparts were used to evaluate the expression and location of ERBB4. Antigen retrieval was done by high pressure for 5 min using citrate buffer (pH 6.0). The sections were incubated overnight with the primary antibodies at 4°C. Negative controls were performed by replacing the primary antibody with phosphate-buffered saline. Finally, the slides were analyzed separately by two pathologists without knowing the patients' clinical information. The staining intensity was scored on a scale of 0-3 as negative (0), weak (1), medium (2) or strong (3) . The extent of the staining, defined as the percentage of positive staining areas of tumor cells in relation to the whole tumor area, was scored on a scale of 0 (0%), 1 (1-25%), 2 (26-50%), 3 (51-75%) and 4 (76-100%). An overall protein expression score (overall score range, 0-12) was calculated by multiplying the intensity and positivity scores.
We score the inflammation severity on a scale of 0 (none), 1(occasionally point necrosis and inflammation), 3 (scattered focal necrosis and inflammation), 6 (frequently seen focal necrosis and inflammation), 9 (piecemeal necrosis and inflammation) and 12 (bridging necrosis and inflammation). The fibrosis severity was scored on a scale 0 (none), 1(limited to portal region), 3 (fibrotic septa formation but intact lobule), 6 (fibrotic ring formation) and 9 (fibrotic septa within fibrotic ring). For staining of proliferating cell nuclear antigen (PCNA), the intensity was scored as − (0-9%), + (10-25%), ++ (26-50%), +++ (51-75%) and ++++ (> 75%).
Gene expression profiling
Liver tissues were harvested in the DEN-induced mice liver tumor models and all mice were 32 weeks old. Microarray analysis was conducted using Affymetrix Mouse Gene 2.1 ST Array according to the protocols recommended by the manufacturer (Affymetrix). Data are available through the Gene Expression Omnibus at the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/geo) as the accession number GSE61056.
RNA extraction and qPCR analysis
Total RNA was extracted using TRIzol Reagent (Takara, China). First-strand cDNA was synthesized using a reverse transcriptase cDNA synthesis kit (Takara, China). For qPCR analysis, aliquots of double-stranded cDNA were amplified using a SYBR Green PCR Kit (Takara, China) and 7500 real-time PCR system (Life Technologies). The primers used for detection of mRNA of genes related in mice and human were in Supplementary Table 1, available at Carcinogenesis Online. GAPDH was amplified as an endogenous control. Comparative quantification of target genes was determined using the 2 −△Ct method.
Cell culture
Hepatoma cell lines Huh-7, HepG2, BEL-7402, Sk-hep-1, QGY-7703, SMMC-7721, MHCC-97H, MHCC-97L, HCCLM6 and SUN-423 from Cell Bank at the Chinese Academy of Sciences (Shanghai, China) were cultured in DMEM medium (Gibco) supplemented with 10% fetal bovine serum (Gibco). The cells were also used and test in our previous study (6) . The cell lines were maintained in a humidified chamber with 5% CO 2 at 37°C. Transfection was performed by Lipofectamine 2000 (Life Technologies) according to the manufacturer's instructions.
Western blot analysis
Cells or tissues were homogenized in RIPA lysis buffer (50mM Tris containing 150mM NaCl, 0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate, pH 7.2) with fresh protease and phosphatase inhibitor cocktail (Merck) on ice for 15 min and centrifuged at 14 500g for 30 min. Protein concentration was determined by BCA Assay (Pierce). 50 μg of proteins were separated electrophoretically on SDS-PAGE gels and transferred onto PVDF membranes (Millipore). ERBB4 antibodies (ab19391) were purchased from Abcam.
Construction of luciferase reporter plasmids
The promoter of TP53INP1 was generated by PCR and cloned into the pGL3-Basic vector (Promega). The primers were used as follows: F: CCG CTC GAG GCC CAC TGT CTC ACT C; R: CCC AAG CTT AGA CGG CAG GCG CGG. The resultant plasmids were designated as pGL3-TP53INP1. All insertions were sequenced to verify the accuracy.
Transfection and luciferase assays
We seeded 5 × 10 5 293T and QGY-7703.The plasmids of pGL3-TP53INP1 were co-transfected with small interfering RNA targeting ERBB4 (siERBB4) or small interfering controls (siCon) (Ruibo, China). All transfections were carried out in triplicate. After 48 hours of incubation, cells were collected and analyzed for luciferase activity with the Dual-Luciferase Reporter Assay System (Promega).
We designed and synthesized four different siRNAs targeting human ERBB4: E1: 5′-GCG CAG GAA ACA UCU AUA UTT-3′, E2: 5′-GCU GAC AGU AGA CCU AAA UTT -3′, E3: 5′-GGU CCU GAC AAC UGU ACA ATT-3′, E4: 5′-GGA GGA AAG AUG CCA AUU ATT-3′. The first two siRNAs targeting ERBB4 were screened as the optimum sequence. Human scrambled siRNA sequence (5′-UUC UCC GAA CGU GUC ACG UTT-3′) was served as a negative control. 
Chromatin immunoprecipitation
Chromatin was cross-linked with 1% formaldehyde. Cells were incubated in lysis buffer (150 mM NaCl, 25 mM Tris pH 7.5, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholate) supplemented with protease inhibitor tablet. DNA was fragmented into ~500 bp pieces using a Branson 250 sonicator. Aliquots of lysates containing 500 µg of protein were used for each immunoprecipitation reaction with anti-ERBB4 (Santa Cruz) or pre-immune IgG. Precipitated genomic DNA was amplified by realtime PCR with the following primers targeting the promoter region of TP53INP1: F: 5′-AAT CCA GAG CGT GCA GCA A -3′; R: 5′-TTC CTG TGA GAG GAA CAT T-3′. The enrichment activity of ERBB4 was compared with pre-immune IgG.
Statistical analysis
The Student's t-test or one-way ANOVA was used to detect the difference of ERBB4 expression between HCC patients with different demographic characteristics or pathologic features. The different survival time according to clinical features, and ERBB4 expression levels was estimated by using the Kaplan-Meier method and compared by the log-rank test. All tests were two-sided unless specified otherwise. All of the statistical analyses were performed with R software (version 3.2.3; The R Foundation for Statistical Computing).
Results
Depletion of ERBB4 in mice leads to more severe cell damage and tumor formation in liver
Without any chemical stimulation, ERBB4 loxp/loxp ;Alb-cre mice older than 6 months developed inflammatory changes spontaneously. Histologically, more inflammatory loci were identified in ERBB4 loxp/loxp ;Alb-cre mice, and CD8 positive lymphocytes or CD 68 positive macrophages were significantly accumulated in ERBB4 loxp/loxp ;Alb-cre mice. Although fibrosis was not obvious after ERBB4 knockout, we still observed more fibrotic area in ERBB4 deficient mice than that in wild-type mice ( Figure 1A) . Generally, hepatocyte injury was more obvious in liver-specific ERBB4 knockout mice with elevated serum alanine aminotransferase levels (15.85 ± 1.23 versus 12.78 ± 0.62, P = 0.026) than that in controls. Interestingly, we found four out of 35 ERBB4 loxp/ loxp ;Alb-cre mice showed clonal expansion, while none of the controls showed the same phenomenon(0/25) ( Figure 1B) . Furthermore, even without clonal expansion, the proliferative rate of hepatocyte was significantly higher in ERBB4-deficient mice than that in controls ( Figure 1C ). In the liver inflammation model, eight pairs of mice were induced by CCl4, which we have established recently (6) (Figure 2A ). We found that intraperitoneal CCl4 injection elicited more severe centrilobular injury compared to those with oil injection. More pale-staining, granular cytoplasm and fatty degeneration were observed in ERBB4 loxp/loxp ;Alb-cre mice ( Figure 2B ). Interestingly, one liver specific ERBB4 knockout mice induced by CCl4 developed grossly visible tumor ( Figure 2C ). And another one developed microscopically visible tumor shown in Figure 2D . So two out of eight ERBB4 loxp/loxp ;Alb-cre mice developed tumor after 18 weeks stimulation of CCl4. This is uncommon in CCl4-induced liver inflammatory models, indicating ERBB4 may be involved in liver tumor formation in the setting of injury.
Loss of ERBB4 contributes to the development of hepatocellular tumor
To further determine the role of ERBB4 in liver malignancy, DEN-induced liver tumor model was applied ( Figure 3A) . Seven of eight male ERBB4 −/−heart mice developed visible hepatic tumor foci, while only two of seven male control mice did ( Figure 3B ). In liver-specific ERBB4 knockout mice, we also observed more tumors than that in controls after DEN treatment ( Figure 3C ).
Then we treat the mice with both DEN and CCl4, a more vigorous way to induce liver tumor ( Figure 3D ). Each mouse developed liver tumor, while ERBB4 −/−heart mice developed significantly more larger liver tumors (>2 mm), and the tumor cells exhibit high grade atypia ( Figure 3E ). All these phenotypes indicate that loss of ERBB4 promotes hepatocellular carcinogenesis.
ERBB4 is down-regulated in tumor samples of HCC and patients with lower expression of ERBB4 had worse survival
In 50 pairs of cancerous and non-cancerous tissues of HCC derived from The Cancer Genome Atlas (TCGA), we found that the expression of ERBB4 was completely lost in most cancerous samples compared with that in non-cancerous tissues ( Figure 4A ). Further, we analyzed ERBB4 protein levels in a commercial tissue microarray of 90 HCC patients by IHC staining. We found that the expression of ERBB4 was significantly weaker in most of the primary HCC tissues than that in its paired normal tissues ( Figure 4B ). Further analysis revealed that lower expression of ERBB4 was correlated to worse differentiation of HCC ( Figure 4C and Supplementary Table 2 , available at Carcinogenesis Online). Importantly, patients with lower level of ERBB4 had worse survival than those with higher level of ERBB4 ( Figure 4D ). In addition, data from GSE5093 also showed that lower ERBB4 expression was correlated with more venous metastatic status of HCC (15) . Generally, these clinical data support that ERBB4 acts as a tumor suppressor in the development of HCC.
Loss of ERBB4 suppresses the expression of the tumor suppressor Trp53inp1
To clarify the mechanism by which ERBB4 deletion leads to cell damage and tumor development in liver, we analyzed the gene expression profile in liver between ERBB4 -/-heart mice and controls. As shown in Figure 5A , about a hundred gene probes were found to be differentially expressed (Fold change > 2). Then we found that 12 genes were down-regulated and one gene upregulated with more than 2.5-fold change when compared the ERBB4 −/−heart mice with controls (Supplementary Table 3 , available at Carcinogenesis Online). The 12 genes were then validated by real-time PCR. Csrnp1, Il1b, Nr4a1 and Trp53inp1 were confirmed significantly down regulated in ERBB4 full or liver-specific knockout mice ( Figure 5B and C) . The human homologue of mouse Trp53inp1 gene is TP53INP1 gene, which is short for tumor protein 53 inducible nuclear protein 1. TP53IPN1 may block tumor progression through p53-dependant and p53-independent pathways (16, 17) . Interestingly, using data from TCGA, we found only TP53INP1 mRNA levels but no other three genes mRNA levels (data not shown) was positively correlated with ERBB4 mRNA levels in normal liver tissues ( Figure 5D ), suggesting the functional link between ERBB4 and TP53INP1. Moreover, in mice liver tissues, we found both Trp53inp1 and Tp53 were reduced in ERBB4 liver specific knockout mice ( Figure 5E ). All these data showed that ERBB4 deficiency lead to down regulation of TP53INP1.
ERBB4 promotes the transcription of TP53INP1
The next question will be how ERBB4 controls gene expression of TP53INP1. Firstly, we analyzed ERBB4 expression at both mRNA and protein levels in a panel of hepatoma cell lines. ERBB4 was expressed at very low level in most hepatoma cell lines except Huh-7, QGY-7703 and MHCC-97L ( Figure 6A ). Interestingly, Huh-7 was established from a 57-year old Japanese diagnosed with well-differentiated liver cancer. MHCC-97H/97L was established from the same patient, one with high metastasis potential (MHCC-97H) and the other with low metastasis potential (MHCC-97L).Again, higher expression of ERBB4 correlates with well-differentiation and lower metastatic potential.
When ERBB4 was transiently knocked down in Huh-7 and QGY-7703 cell lines, the expression of TP53INP1 was reduced ( Figure 6B ). Conversely, overexpression of ERBB4 will enhance the mRNA expression level of TP53INP1 ( Figure 6C) . To test the effect of ERBB4 on gene expression of TP53INP1, the promoter region of TP53INP1 was cloned to a luciferase reporter system to evaluate gene regulation. We found that knockdown of ERBB4 significantly decreases the luciferase reporter activity of TP53INP1 ( Figure 6D ), indicating ERBB4 acts as a co-transcriptional factor for TP53INP1 gene expression. Importantly, in vitro chromatin immunoprecipitation assay revealed that ERBB4 could directly bind to the promoter of TP53INP1 gene ( Figure 6E ). In ERBB4 knockout mice, expressions of trp53inp1 in parts of liver cells were lost and expressions of p53 in liver cells were significantly down-regulated. While in control mice, Trp53inp1 was homogeneously expressed in the cytoplasm of liver cells and tp53 was highly expressed in the nucleus of the liver cells ( Figure 6F ).Using data from TCGA, we found significant positive correlation between TP53INP1 and TP53 in TP53 non-mutated cancerous tissues of HCC ( Figure 6G) . Our results suggest a potential mechanism for the role of ERBB4 in HCC by inhibiting P53 activity through TP53INP1 pathway.
Discussion
The ERBB tyrosine kinases (EGFR, ERBB2/HER2, ERBB3 and ERBB4), are widely expressed in many tissues, playing the key roles in both physiological and pathological processes (18) . Here, we uncover ERBB4 as a suppressor in the development of HCC. For a long time, ERBB4 is regarded as an oncogene in cancer development as well as other ERBB family members. ERBB4 promotes growth of human breast cancer cells (19, 20) and transforms mammary epithelial cells into malignant phenotype (21) . Nevertheless, the physiological role of ERBB4 is largely ignored. In fact, ERBB4 is also a very important factor for homeostasis in gut and lung. Down regulation or knockout of ERBB4 will lead to more severe inflammatory response in gut or lung (5, 19, 22) . Recently, we also reported a protective role of ERBB4 in HBV hepatitis and related liver inflammation (6) . Furthermore, in this study, we found that loss of ERBB4 trigged liver tumor formation both in our liver inflammatory mice model and in old mice spontaneously. Liver tumor mice models also revealed that loss of ERBB4 caused more and larger tumor formation. Our clinical data also showed that lower expression of ERBB4 was correlated with worse differentiation and poor survival of HCC.
We also found that ERBB4 played as a co-factor for gene transcription. Traditionally, ERBB4 acts as cell-surface receptor for the signal transduction. Recently it has been found that ERBB4 protein may break into several pieces and release a cytoplasmic intracellular domain after binding to the ligand. Then, intracellular domain will translocate to the nucleus and act as co-transcriptional factor, which leads to activation of gene expression (5, 19) . Our study showed that down-regulation of ERBB4 would result in transcriptional repression of TP53INP1. Mechanistically, we found that down regulation of TP53INP1 was functionally correlated with ERBB4 knockout. As we know, TP53INP1 is a key tumor suppressor by enhancing p53 function and repressing tumorigenesis (23) . Moreover, we found that loss of ERBB4 can attenuate the expression of TP53INP1, which would subsequently suppress the expression of p53.
Our data also suggested that the functional role of ERBB4 in cancer development depends on cancer types or context ERRB4 involved in. It has been found that the expression pattern of ERBB4 in cancerous tissues and normal tissues of HCC is different from that of other ERBB family members (24) . Data from TCGA also showed that ERBB4 was lost in most cancerous samples compared with that in non-cancerous tissues of HCC patients, indicating ERBB4 is important for the homeostasis of liver cells. In addition, an elegant paper has reported that EGFR is also important for the homeostasis in gut and loss of EGFR will exacerbate colitis-associated cancer in mice (25) , which uncover a paradoxical tumor-suppressing role for EGFR. Therefore, the role of ERBB4 and the precision mechanisms are still needed to be carefully studied in different settings.
In summary, our study found a suppressive role of ERRB4 in HCC and impairment of ERBB4 will promote HCC development by inhibiting TP53INP1 expression.
